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Abstract
Background: Statins are drugs that are used to lower plasma cholesterol levels. Recently, contradictory claims have been
made about possible additional effects of statins on progression of a variety of inflammatory disorders, including infections.
We therefore examined the clinical course of patients admitted to hospital with 2009 pandemic influenza A(H1N1), who
were or weren’t taking statins at time of admission.
Methods: A retrospective case-control study was performed using the United Kingdom Influenza Clinical Information
Network (FLU-CIN) database, containing detailed information on 1,520 patients admitted to participating hospitals with
confirmed 2009 pandemic influenza A(H1N1) infection between April 2009 and January 2010. We confined our analysis to
those aged over 34 years. Univariate analysis was used to calculate unadjusted odds ratios (OR) and 95 percent confidence
intervals (95%CI) for factors affecting progression to severe outcome (high dependency or intensive care unit level support)
or death (cases); two multivariable logistic regression models were then established for age and sex, and for age, sex,
obesity and ‘‘indication for statin’’ (e.g., heart disease or hypercholesterolaemia).
Results: We found no statistically significant association between pre-admission statin use and severity of outcome after
adjustment for age and sex [adjusted OR: 0.81 (95% CI: 0.46–1.38); n = 571]. After adjustment for age, sex, obesity and
indication for statin, the association between pre-admission statin use and severe outcome was not statistically significant;
point estimates are compatible with a small but clinically significant protective effect of statin use [adjusted OR: 0.72 (95%
CI: 0.38–1.33)].
Conclusions: In this group of patients hospitalized with pandemic influenza, a significant beneficial effect of pre-admission
statin use on the in-hospital course of illness was not identified. Although the database from which these observations are
derived represents the largest available suitable UK hospital cohort, a larger study would be needed to confirm whether
there is any benefit in this setting.
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Introduction
In March 2009 the first human cases of a novel strain of
pandemic influenza A(H1N1; hereafter pH1N1) virus of swine
origin were reported from the United States; within three months
global spread had occurred leading to the declaration of a
pandemic by the World Health Organization. Whilst the majority
of cases were mild or sub-clinical, about 1% of patients required
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admission to hospital [1], of whom about 15% required critical
care support and an estimated 5–10% died [2–4]. Thus, even a
relatively mild pandemic can have a considerable local and global
impact, and inexpensive measures to reduce the effect of future
pandemics remain an urgent priority.
Statins (three- hydroxy 3- methylgluteryl co enzyme A reductase
inhibitors) are drugs indicated for control of plasma cholesterol. In
addition, they have wide-ranging down-regulatory effects on
inflammatory and immune mechanisms. Moreover, there is a
body of circumstantial evidence that current treatment with statins
may beneficially alter the natural history of infectious diseases,
specifically reducing the likelihood of significant bacterial infection
progressing to severe sepsis and septic shock [5–7]. It has been
proposed that superadded bacterial infection was an important
contributor to the substantial mortality associated with the 1918/
19 pandemic [8]. In addition, a quarter of adults admitted to
hospital and included in the Influenza Clinical Information
Network database during the pH1N1 pandemic had clinically or
radiographically apparent pneumonia [9], and there are reports
that just under one third of such pneumonia cases had bacterial
co-infection [10–12]. The anti-inflammatory effects of statins
might have clinical benefits if severe disease is driven by over
exuberant cytokine responses [13], as suggested in severe cases of
both H5N1 and H1N1 influenza [14,15]. It has thus been argued
that during a period of high pandemic risk, the widespread
administration of statins may be a clinically useful and cost
effective public health measure [16,17].
The Influenza Clinical Information Network (FLU-CIN)
collected clinical, epidemiological and outcome data on patients
admitted to participating UK hospitals with confirmed pH1N1
influenza infection. Data were also collected on medications taken
by patients at the time of admission and on antibiotics, antivirals
and steroids during hospital admission.
The aim of this retrospective database analysis was to establish
whether there is evidence that patients who were taking statins at
the time of hospital admission for pH1N1 influenza were less likely
to die or require critical care support during their illness than
patients not taking statins.
Methods
Between April 2009 and January 2010, FLU-CIN collected
clinical, epidemiological and outcome data on patients admitted to
participating UK hospitals with confirmed pH1N1 influenza
infection. Seventy five hospitals in 31 cities or towns provided data.
The details of data collection and the overall findings from the first
wave of the 2009 pandemic have been described elsewhere [2].
Briefly, pH1N1 influenza infection was diagnosed by a positive
reverse transcriptase polymerase chain reaction (PCR) result from
respiratory samples obtained during the admission episode. A
dataset was collected by specifically trained data collectors which
included demography, acute and long-term medications, clinical
observations, clinical course and outcome. FLU-CIN was a public
health surveillance project for which the Ethics and Confidentiality
Committee of the National Information Governance Board for
Health and Social Care in England approved the collection,
storage and use of personal data without the need for individual
participant consent. This report represents a secondary analysis of
the entire FLU-CIN database which includes data on patients
from both waves of the UK pH1N1 experience.
Patients
The entire FLU-CIN database included 1,520 patients, of
which 601 were from the first wave (25th April to 31st August
2009), and 919 patients from the second (1st September–27th
January 2010). Patients aged less than 35 years were excluded
from this analysis, since few young people use statins, all others
were included (n = 571). Cases were defined as patients who
suffered a severe outcome (critical illness or death) whilst controls
were those who did not.
Analysis and statistical methodology
We used a case-control analysis to investigate the association
between pre-admission statin use and severe outcome from
influenza infection. Our exposure variable was ‘pre-admission
statin use (yes/no)’ as recorded in the case note current drug
history. For the purpose of the analysis we did not categorise statin
use by type, duration or dosage. We defined ‘severe outcome’
(cases) as those patients requiring admission to level 2 (high
dependency unit) or level 3 (intensive care unit) or who died (Data
S1).
We used an a priori conceptual framework to determine potential
confounding variables in the multivariate logistic regression rather
than a statistical approach. We adjusted for age, sex, physician-
defined obesity and ‘indication for statin’ (this binary variable was
coded as ‘yes’ if the subject had any one of the following recorded
in their case notes: heart disease- predominantly ischaemic heart
disease and cardiac failure, cerebrovascular disease, hypercholes-
terolemia). This latter variable was developed to ameliorate the
potential for ‘‘confounding by indication’’, as statin use is
associated with co-morbid states which contribute to additional
individual clinical risk for worse outcomes in many clinical
situations.
We used univariate analysis to calculate unadjusted odds ratios
(OR) and 95 percent confidence intervals (95% CI), then two
multivariable logistic regression models to calculate adjusted ORs
and 95%CIs. Model 1 adjusted for age and sex, and model 2 for
obesity and ‘indication for statin’ in addition to age and sex. We
also carried out a number of sensitivity analyses: to explore level
2/3 admission and death separately as outcome measures, to look
for a healthy user effect, and to determine impact of other co-
morbidities not associated with statin use. We used Stata (version
11) for all statistical analyses
Results
Our study sample comprised 571 patients aged 35 years and
above (44% male, mean age: 52 years 611.8) of whom 94/571
(16.5%; Table 1) had been taking statins at the time of hospital
admission and 121/571 (21.2%) progressed to severe outcome; the
profile of statins recorded was simvastatin 62%, atorvastatin 30%,
rosuvastatin 5%, pravastatin 2%, unspecified 1%. Table 1
summarizes patient characteristics associated with severe outcomes
in influenza patients. Women appeared to be at a lower risk of
severe outcome than men [crude OR: 0.45 (95% CI: 0.30–0.68)].
As reported previously [14], C-reactive protein levels higher than
30 mg/l were associated with severe outcomes [crude OR: 3.28
(95% CI: 1.27–8.25)] and the likelihood of severe outcome
increased further with levels greater than 100 mg/l [crude OR:
15.27 (95% CI: 6.06–38.43)]. We failed to find a statistically
significant association between pre-admission statin use and severe
outcome [crude OR: 0.93 (95% CI: 0.46–1.44)].
Table 2 presents the results of the multivariable logistic
regression. We found no statistically significant association
between pre-admission statin use and severe outcome after
adjustment for age and sex [adjusted OR: 0.81 (95% CI: 0.46–
1.38)]. Even after adjustment for age, sex, obesity and indication
for statin, the association between pre-admission statin use and
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severe outcome failed to reach statistical significance although the
point estimates are compatible with a clinically significant
protective effect [adjusted OR: 0.72 (95% CI: 0.38–1.33)].
A number of sensitivity analyses were performed. First, level 2/3
admissions and death were considered as separate outcomes. After
adjusting for age, sex, obesity and indication for statins, pre-
admission statin use was associated with a decreased risk of death
[adjusted OR: 0.64 (95% CI: 0.25–1.65)] and level 2/3 admission
[adjusted OR: 0.66 (95% CI: 0.33–1.29)] but again, these results
did not reach statistical significance. A second analysis was
conducted to explore whether statin use was simply a marker for
the ‘healthy user effect’ (implying that statin users were healthier
than non-users at baseline thereby explaining the observed
decrease in severe outcomes). However, conditions that are
common ‘indications for statin’ (hypercholesterolemia, cerebro-
vascular disease, cardiovascular disease) are serious comorbidities
Table 1. Univariate analysis of factors influencing severe outcomes in pH1N1 patients, ages 35 years and above (n = 571).
Patient characteristic Category
Cases (severe
outcomes)
(n=121) (%)
Controls
(n=450) (%)
Unadjusted OR
(95% CI) P value
Statins No 102 (84.3) 375 (83.3) 1.00 0.800
Yes 19 (15.7) 75 (16.7) 0.93 (0.54–1.61)
Age group 35–44 41 (33.9) 173 (38.4) 1.00
44–54 33 (27.3) 134 (29.8) 1.04 (0.63–1.73)
55–64 30 (24.8) 85 (18.9) 1.49 (0.87–2.55)
65–74 14 (11.6) 41 (9.1) 1.44 (0.72–2.89)
$75 3 (2.5) 17 (3.8) 0.74 (0.21–2.66) P trend = 0.318
Sex Male 72 (59.5) 180 (40.0) 1.00
Female 49 (40.5) 270 (60.0) 0.45 (0.30–0.68) ,0.001
Ethnicity White 57 (47.1) 196 (43.6) 1.00
Other 26 (21.5) 136 (30.2) 0.66 (0.39–1.10) 0.109
Missing 38 (31.4) 118 (26.2) 1.11 (0.69–1.77) 0.671
Statin indication No 103 (85.1) 393 (87.6) 1.00
Yes 18 (14.9) 57 (12.6) 1.21 (0.68–2.14) 0.518
C-reactive protein (mg/l) ,30 6 (5.0) 105 (23.3) 1.00
31–99 21 (17.4) 112 (24.9) 3.28 (1.27–8.45) 0.014
.100 41 (33.9) 47 (10.4) 15.27 (6.06–38.43) ,0.001
Missing 53 (43.8) 53 (43.8) -
Obese No 111 (91.7) 423 (94.0) 1.00
Yes 10 (8.3) 27 (6.0) 1.41 (0.66–3.00) 0.371
Smoking No 54 (44.6) 227 (50.4) 1.00
Yes 36 (29.8) 104 (23.1) 1.46 (0.90–2.35) 0.127
Missing 31 (25.6) 119 (26.4)
Cardiovascular disease No 83 (68.6) 339 (75.3) 1.00
Yes 38 (31.4) 111 (24.7) 1.40 (0.90–2.17) 0.135
Cerebrovascular disease No 121 (100.0) 446 (98.9) 1.00
Yes 0 (0.0) 5 (1.1) -*
Diabetes No 102 (84.3) 395 (87.8) 1.00
Yes 19 (15.7) 55 (12.2) 1.34 (0.76–2.35) 0.313
Immunocompromised status No 115 (95.1) 433 (96.2) 1.00
Yes 6 (4.9) 17 (3.8) 1.33 (0.51–3.45) 0.559
Charlson comorbidity index score 0 47 (38.8) 164 (36.4) 1.00
1–2 62 (51.2) 225 (50.0) 0.96 (0.63–1.48) 0.858
3–5 12 (9.9) 57 (12.7) 0.74 (0.36–1.48) 0.389
.5 0 (0.0) 4 (0.9) -
Length of hospital stay ,2 days 2 (1.7) 60 (13.3) 1.00
$2 days 66 (54.6) 348 (77.3) 5.69 (1.36–23.85) 0.017
Missing 53 (43.8) 42 (9.3) -
Note: Statistically significant results in bold.
(*could not be calculated because of insufficient data).
doi:10.1371/journal.pone.0018120.t001
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that can generally affect health in an unfavorable way. In our
cohort, we found that statin users were more likely to have a
condition that would qualify as a ‘statin indication’ (unadjusted
OR 45.32, 95% CI: 25.76–79.73, p,0.001). Finally, we added a
further balancing term to Model 2 which was the presence or
absence of a co-morbidity not normally directly associated with
statin use (hypertension; asthma; chronic lung, liver or renal
disease; diabetes or other metabolic disease; chronic neurological
disease). This did not affect the outcome (adjusted OR 0.71 (95%
CI: 0.38–1.33).
Discussion
In this retrospective secondary analysis, we were unable to
demonstrate a statistically significant impact of statins on the
progression of influenza to a severe outcome in patients
hospitalized during the UK 2009 pandemic. Whilst not achieving
significance, our effect point estimates are consistent with
previously published positive reports [5–7,18,19]. We are
therefore unable to confidently exclude a beneficial effect of statin
use in patients with severe influenza.
There is evidence from sepsis research that statins ameliorate
inflammatory and immunological function by so-called pleiotropic
effects on leukocyte-endothelial interaction, intra- and inter-
cellular signaling, inflammatory gene transcription, haem-oxygen-
ase expression and expression of MHC class II antigens [13]. The
net effect is thought to be a general ‘‘damping-down’’ of
inflammatory state. There is some modest supporting evidence
from a trial of simvastatin in suspected or proven bacterial
infection; reductions in tumor necrosis factor-a and interleukin-6
were demonstrated in the statin treated arm [20]. A variety of
epidemiological studies have generally been further supportive of
this hypothesis, suggesting that statins may have a beneficial effect
in modifying severe responses to infectious insults in general
populations [5–7], and chronic renal failure patients [21].
A detailed review of these and other individual studies lies
outside the scope of this paper but two thorough meta-analyses
have been published recently [22,23]. Search strategies differed
somewhat and spanned different epochs, but the conclusions were
broadly similar. Tleyjeh and colleagues concluded that there was
evidence that statins appeared overall beneficial in the prevention
and treatment of infections [22], although the authors identified
weak effects in some studies and some evidence of publication bias.
Janda and colleagues more recent synthesis concluded that there
was a protective effect of statins in patients with sepsis and/or
other severe infections [23]; the authors felt their results were
limited by the cohort-nature of some included studies and trial
outcome heterogeneity.
Several important studies relevant to the current report deserve
brief discussion [18–19,24–26]; a number of these were commu-
nity-focused and thus not included in the meta-analyses. As
respiratory impairment is a key factor in progression to severe
outcome, the effect on clinically important pneumonia, which may
of course be bacterial or viral is a key question. In a community
cohort study of 3,681 patients with pneumonia [18], Myles and
colleagues observed that current statin use was associated with a
67% reduction in 30 day mortality (adjusted hazard ratio 0.33,
95%CI 0.19–0.58), and a 55% reduction in long term mortality
(adjusted hazard ratio 0.45, 95%CI 0.32–0.62). In a related report
from the same group [19], current statin use was associated with a
reduced risk of developing pneumonia (odds ratio 0.78, 95%CI
0.65–0.94).
By contrast, a matched case control study of people aged over
65 years [24], did not demonstrate a clear positive benefit. The
investigators identified 1,125 cases of pneumonia and 2,235
matched controls; current statin users represented 16.1% of cases
and 14.6% of controls (adjusted odds ratio 1.26, 95%CI 1.01–
1.56). Similarly, statin use was present in 17.2% of cases admitted
to hospital and 14.2% of matched controls (adjusted odds ratio
1.61, 95%CI 1.08–2.39).
A study of 3,415 hospitalized patients with pneumonia appeared
to show a reduction in critical care admission and mortality [25]
(included in both meta-analyses) in patients previously treated with
statins. However, this beneficial effect disappeared after adjust-
ment for confounders and statin use may even have been
associated with potential harm. A long term community study
over several winters [26], including data on nearly a third of a
million patient years, failed to demonstrate an impact of statin
Table 2. Multivariable analysis: association between pre-admission statin use and severe outcomes in pH1N1 influenza.
Exposure
Unadjusted odds ratio
(95% CI)
Model 1: Adjusted odds
ratio (95% CI)
Model 2: Adjusted odds ratio
(95% CI)
Pre-admission statin use No 1.00 1.00 1.00
Yes 0.93 (0.46–1.44) 0.81 (0.46–1.38) 0.72 (0.38–1.33)
Age-group (years) 35–44 1.00 1.00 1.00
45–54 1.04 (0.63–1.73) 1.05 (0.62–1.76) 1.06 (0.63–1.79)
55–64 1.49 (0.87–2.55) 1.48 (0.85–2.57) 1.50 (0.86–2.62)
65–74 1.44 (0.72–2.89) 1.44 (0.70–2.99) 1.48 (0.71–3.09)
$75 0.74 (0.21–2.66) 0.64 (0.18–2.32) 0.64 (0.17–2.33)
Sex Male 1.00 1.00 1.00
Female 0.45 (0.30–0.68) 0.45 (0.30–0.68) 0.45 (0.29–0.67)
Statin indication No 1.00 1.00
Yes 1.21 (0.68–2.14) -NA- 1.23 (0.65–2.33)
Obese No 1.00 1.00
Yes 1.41 (0.66–3.00) -NA- 1.66 (0.75–3.67)
Model 1: adjusted for a priori confounders age and sex.
Model 2: adjusted for age, sex, indication for statin and obesity.
doi:10.1371/journal.pone.0018120.t002
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treatment on the incidence of respiratory infection, although there
was a significant reduction in urinary tract infections.
What these epidemiological studies lack are robust microbio-
logical data differentiating bacterial and viral causes of pneumo-
nia. A report of the Australasian critical care pandemic influenza
pH1N1 influenza cohort (n = 689) reported a viral pneumonitis
rate of 48.8%, and a secondary bacterial pneumonia rate of 20.3%
[11]. A recent Canadian study of critically ill pandemic influenza
patients reported a secondary bacterial pneumonia rate of 24.4%
[12]. Acute respiratory failure in patients without a clear diagnosis
of viral pneumonitis or bacterial pneumonia may be due to acute
lung injury associated with multiple organ failure, exacerbation of
underlying respiratory or cardiac disease, fluid overload or other
causes. The proportion of patients whose disease progression is
due to bacterial superinfection may be a critical variable in
understanding the effect of statins, since uncomplicated viral lung
disease may be less affected by statin use.
There are a number of possible explanations for our findings.
First, the benefits of statins may be too modest for our study to
detect. (type 2 error). The event rate (progression to severe
outcome) for the statin naı¨ve group (n = 477) was 21.4%, and
20.2% for prior statin treated patients (n = 94; p = 0.8).
This study was an opportunistic study arising from access to the
pandemic influenza surveillance database and we did not perform
prior sample size calculations. We decided to carry out a post-hoc
power calculation based on estimates of statin effect from previous
reports [18,19]. Assuming a probability of statin use of 0.17 and a
30 percent decrease in severe outcomes for influenza with statins,
we estimated that a future case control study would require 637
cases and 2,548 controls to meet the standard criteria of 80
percent power. This suggests that our present study may have been
underpowered, which could explain why we did not observe a
statistically significant effect. Interestingly, our point estimate
(0.72) was very close to previous study estimates of the protective
effect of statins on pneumonia-related mortality (although clearly
this could have been a chance finding). A second limitation is that
our analysis is confined to hospitalized cases. If statins reduce the
severity of influenza in non-hospitalized patients, cases reaching
the threshold for hospitalization despite statin use may have an in-
hospital course similar to that seen in non-users of statins. Third,
we did not record whether statin therapy continued after
admission to hospital. We cannot therefore determine whether
stopping or continuing statin therapy affected outcome. Last, there
may be no or little class effect of statins on disease severity during
influenza infection; the majority of patients were taking simvas-
tatin, the dataset was not large enough to explore for effects of
individual statin drugs. We do not know what proportion of
patients progressed to severe outcome because of pathological
processes affected by statins and how many patients progressed for
other reasons. Our cohort was not large enough to justify
subgroup analyses, and we are therefore unable to exclude
beneficial effects in certain patient groups.
In conclusion, we were unable to show a beneficial effect of
prior statin use on the in-hospital course of illness in patients
admitted with pH1N1 influenza. Although the database from
which these observations are derived represents the largest UK
hospital cohort with detailed pre-admission data, it is possible that
a significant beneficial effect has been missed and that a larger
study could reveal a clinically significant benefit from statin
administration.
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